Suppression of neuroblastoma growth by dipeptidyl peptidase IV: Relevance of chemokine regulation and caspase activation

Imbalanced protease expression and activities may contribute to the development of cancers including neuroblastoma. Neuroblastoma is a fatal childhood cancer of the sympathetic nervous system that frequently overexpresses mitogenic peptides, chemokines and their receptors. Dipeptidyl peptidase IV (DPPIV), a cell surface serine protease, inactivates or degrades some of these bioactive peptides and chemokines, thereby regulating cell proliferation and survival. Our studies show that DPPIV is expressed in normal neural crest-derived structures, including superior cervical and dorsal root ganglion cells, sciatic nerve, and in adrenal glands, but its expression is greatly decreased or lost in cells derived from neuroblastoma, their malignant counterpart. Restoration of DPPIV expression in neuroblastoma cells led to their differentiation in association with increased expression of the neural marker MAP2 and decreased expression of chemokines including stromal-derived factor 1 (SDF1) and its receptor CXCR4. Furthermore, DPPIV promoted apoptosis, and inhibited SDF1 mediated in vitro cell migration and angiogenic potential. These changes were accompanied by caspase activation, and decreased levels of phospho-AKT and MMP9 activity, down stream effectors of SDF1-CXCR4 signaling. Importantly, DPPIV suppressed the tumorigenic potential of neuroblastoma cells in a xenotransplantation mouse model. These data support a potential role for DPPIV in inhibiting neuroblastoma growth and progression.